Moderna expects minimum Covid-19 vaccine sales of $5B in 2023

Earlier, Moderna reiterated 2023 expected minimum COVID-19 vaccines sales of approximately $5B from confirmed Advance Purchase Agreements and 2022 contract deferrals. In other news, Moderna said the mRNA-1010 Southern Hemisphere immunogenicity study in adults is fully enrolled, with a data readout expected in 1Q23, and the mRNA-1010 Northern Hemisphere efficacy study in older adults is fully enrolled, with the data readout that could occur this winter depending upon cases accrued in the study and vaccine efficacy. Moderna also said that the Phase 3 RSV study of has now accrued the cases required to complete the first interim efficacy analysis.